Deutscher Fußball-Bund stellte Logo der deutschen Bewerbung zur EURO 2024 vor - Düsseldorf einer der Standorte
Düsseldorf (ots) - Gerade hat der Deutsche Fußball-Bund die offizielle Bildmarke zur Bewerbung um die ...
Düsseldorf (ots) - Gerade hat der Deutsche Fußball-Bund die offizielle Bildmarke zur Bewerbung um die ...
Im Herbst zu den Kreativ-Regionen Österreichs reisen: Straß im Straßertale (ots) - Bei "Kreativ Reisen ...
München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
Amsterdam (ots/PRNewswire) - Piramal Enterprises, Fujifilm Diosynth Biotechnologies and Vision Consulting
Outline Market Predictions
ADCs, multiuse facilities and regulatory transparency and integration seen
as the key drivers of tomorrow's healthcare targets
CPhI Worldwide [http://www.cphi.com] and CPhI Pharma Evolution [http://www.pharmaevolution.com], part of UBM Live's Pharmaceutical Portfolio, announce the release of the first section of its annual report - with forward looking article submissions from Piramal Enterprises, Fujifilm Diosynth Biotechnologies and Vision Consulting - examining the global implications of regulatory failure, single use technologies and the potential of antibody drug conjugates (ADC).
The outlook for the next few years is particularly optimistic for the ADCs market where Piramal Enterprises Executive Director and COO Vijay Shah envisages increased global investments and even the arrival of a new blockbuster drug to treat solid tumours. However, beyond the traditional cancer uses of ADCs he also forecasts this class of therapeutics will provide indications such as inflammation - demonstrating that ADCs are on the cusp of being the great break-through that many analysts have predicted. Unsurprisingly, in the short term the majority of ADCs will be for lymphoma treatment, but IND (Investigational New Drug) submissions for this class of drug will rise over 50% in the next five years - and ultimately the market will grow to $10bn during the next 10 years. With such an increase in the prevalence of new targets it's really only a matter of time before we see ADCs providing therapeutic solutions to a range of conditions and this market is likely to grow enormously over the next five, 10 and even 20 years.
"In the past a major failing with ADCs has been that cytotoxic agents were simply not active enough to kill the target cell with such a small amount of payload - 0.01% - however, new technologies that improve antibody and antigen conjugation could hold the key to really unlocking their potential. Over the next 10 years we will see ADCs with much higher penetration rates." - Vijay Shah
Fujifilm Diosynth Biotechnologies Senior Vice President of R&D and Innovation, Mark Carver, warned however that unless we move towards a "health based risk assessment" approach to single use technologies, innovation could be compromised - particularly for promising targets like ADCs that are often required to be manufactured in such facilities. The problem for biologics is that single use facilities are hugely increasing the costs of development and putting at risk promising targets that are deemed unviable before their true potential has been explored. With EMA guidelines likely to exacerbate this trend, many innovative targets are likely to struggle to make it into clinical trials.
The solution to this problem is health based approaches, so that even when there is only partial data on early phase development work and the likely doses they will be used at to support full PDE and MACO (Maximum allowable carryover) values there is still sufficient information to produce appropriate banding to evaluate risk. The cost reductions and increase in innovation will help accelerate the development of new biologics product classes and it's now up to the regulators to implement these changes into the way assessments are conducted that maintain safety without compromising innovation.
Similarly, Vision Consulting CEO Dilip Shah has collectively examined the current regulatory environment and concludes that safety and compliance can be both increased by regulators simplifying and unifying their codes and working closer with industry. The problem, however, is that over the last few years and into the foreseeable future we are likely to see an increased number of deliberate infringements (FDA warning letters), particularly as analytical technologies increase. The resultant implication of these well publicised large pharma infringements is that there is now a very real threat that increasingly restrictive regulations will prevent smaller, more innovative players entering the market. The answer, Dilip Shah believes, will ultimately lie in producing a more transparent process - and crucially one that is unified across the globe - whereby regulators take a more active role in working industry to evaluate procedures in a transparent and consultative manner. However, for this new outcomes-based approach to be successfully implemented, it would require global collaboration amongst regulators, which is still something Dilip Shah does not believe will happen for at least another five years.
CPhI and Pharma Evolution will release its remaining annual report findings (10 further expert submissions) at CPhI 2013 , with a closed session press conference on the reports taking place on the first day of the event.
Agnes Shanley - Editor at CPhI Pharma Evolution - commenting on the first part of the report's release: "This first part of the CPhI Phama Evolution annual report, which has been produced with the help of our global expert panel, clearly highlights the growth in biologics and multiuse technologies that will help over the next five years to re-invigorate a period of innovative medicines coming to market- with much excitement and anticipation focussed on ADCs. However, from what we have seen within these first report submissions, it is clear that regulatory reform will be essential to maintaining safety whilst creating an environment that is as flexible as the marketplace to help induce increased innovation."
Chris Kilbee - Group Director, CPhI & Pharma, confirmed the intention to distribute the full findings at this year's event: "At CPhI we will be releasing the remaining 10 articles from our panel members, which collectively will produce an in-depth overview of the market and will enable the industry to take stock and look at the implications over the next few years. We have designed these to be open access and to increase discussion amongst the industry, so I would encourage people to read the full submissions to get a fuller picture of our experts' perspectives. I must also take this opportunity to thank our panel for taking the time to provide their perspectives within this report."
For full copies of the submissions and overall reports please visit: http://downloads.deusm.com/pharmaevolution/CPhI-Annual-Industry-report-part-I.pdf
Antibody drug conjugates (ADC):
- Blockbuster drug for solid tumours predicted in next 10 years - ADCs will come to market for indications beyond cancer, such as inflammation, with a total market value of $10 billion by 2023 - Majority of ADCs for next five years will be for Lymphoma - IND submissions expected to rise 50% over the next five years
Single- verses multi- use technologies:
- Within next five years it is projected that the industry will be forced to move to 'health-based approach' to risk assessment in order to reduce costs - Investigational medicinal products with limited data could start to be produced in multiuse facilities - EMA guidelines, if implemented fully, put innovation at risk by forcing manufacturer in fully dedicated facilities - this could even prevent some promising biologics target making it to clinical trial
- Tighter regulations as a result of large pharma infringements will prevent smaller, more innovative companies entering the US market - reducing competitiveness - More open transparent regulator could help facilitate improved standards - A simpler global system must be found in order to improve regulatory compliance, safety and innovation - FDA warning letters predicted to rise over the next five years as analytical technologies rise - Large-scale integration of regulators unlikely despite the clear advantages this would bring - Deliberate infringements are on the rise
Notes to editors
About CPhI Pharma Evolution annual report and expert industry panel
Earlier this year, CPhI launched a major new initiative with the introduction of its annual report published in cooperation with Pharma Evolution - written by a panel of world-leading experts across the pharmaceutical supply chain.
The vision was to harness the power of CPhI's independent position within the industry so that it could produce unbiased analysis of the global pharmaceutical industry and help bring different perspectives together.
The annual report utilises expert in-depth essays, looking at future contingencies. Experts were given carte blanche to evaluate current industry practices and examine the future implications for the industry.
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, China, India, Japan, Southeast Asia, Russia and South America co-located with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com.
For more information visit: http://www.cphi.com
The UBM Live annual schedule of Pharmaceutical events also includes CPhI Worldwide, ICSE, P-MEC Europe and InnoPack ; CPhI and P-MEC India (3-5 December, 2013 at the Bombay Exhibition Centre in Mumbai); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan ; CPhI Russia and IPhEB (16-17 April, 2014 in St Petersburg, Russia); CPhI, P-MEC and Innopack South East Asia (20-22 May, 2014 in Jakarta, Indonesia); CPhI Istanbul (4-6 June, 2014, Turkey) and CPhI, Hi and Fi, ICSE, P-MEC, BioPh and LabWorld China (26-28 June, 2014 at SNIEC, Shanghai, China).
About CPhI Pharma Evolution
CPhI Pharma Evolution (http://www.pharmaevolution.com) launched in February 2013 as a global online community where professionals from across the pharmaceutical manufacturing sector can talk with their peers and share best-practices and regulatory updates across the pharmaceutical ingredient and contract manufacturing space. Pharma Evolution is the new go-to community for industry professionals to exchange thoughts and network on key areas including: formulation, APIs, excipients, drug delivery, R&D, manufacturing and quality, packaging and anti-counterfeiting, regulatory compliance, and outsourcing and supply chain management. Pharma Evolution was created as an extension of CPhI's global events business as a forum and resource for pharmaceutical executives to employ 365 days a year. Pharma Evolution is published by CPhI and UBM DeusM (http://www.deusm.com), the marketing services division of UBM specializing in building and operating highly engaged communities of qualified users within specialist B2B markets, using a strategy of best-practices focused on content and technology.
About UBM Live
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact: Alex Heeley or Tristan Jervis De Facto Communications T: +44(0)207-203-6745 / 6740 E: firstname.lastname@example.org / email@example.com